Announced details
The Company has an agreement with Janssen Biotech, Inc. and Alvotech hf. dated 4 November 2025. Details of the contractual relationship are not disclosed.
Janssen Biotech, Inc. is based in Pennsylvania, United States. Alvotech hf. is based in Iceland. Other details are not disclosed.
Marketing approval
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Golimumab BS Subcutaneous Injection 50 mg Autoinjector “F”, Golimumab BS subcutaneous injection 50 mg syringe “F” |
| Counterparty | Janssen Biotech, Inc., Alvotech hf. |
| Counterparty overview | Janssen Biotech, Inc. is based in Pennsylvania, United States. Alvotech hf. is based in Iceland. Other details are not disclosed. |
| Relationship with the Company | The Company has an agreement with Janssen Biotech, Inc. and Alvotech hf. dated 4 November 2025. Details of the contractual relationship are not disclosed. |
| Contract Date | 4 November 2025 (stated as the date the agreement was announced) |
| Launch date | Reimbursement listing and launch possible from May 2027 onward (planned) |
| Applicable area | Rheumatoid arthritis inadequately controlled by existing treatments, including prevention of structural joint damage, Improvement and maintenance therapy for moderate to severe ulcerative colitis, limited to cases inadequately controlled by existing treatments |
| Award/certification name | Marketing approval |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand the choice of administration devices alongside the existing syringe formulation, improving patient convenience and meeting the diverse needs of healthcare providers. The Company has positioned its biosimilar business as one of its growth strategies under its medium-term management plan.